A Single-blind, Randomised, Placebo-controlled, Parallel Group Study to Investigate Safety, Tolerability, Pharmacokinetics and the Effects on Cardiac Function of Repeat Oral Doses of SB-649868 in Adult and Elderly Healthy Volunteers.
Latest Information Update: 08 Oct 2023
At a glance
- Drugs GSK 649868 (Primary)
- Indications Sleep disorders
- Focus Adverse reactions
- Sponsors GSK
Most Recent Events
- 20 May 2011 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
- 20 May 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 26 Dec 2009 New trial record